1. Home
  2. CPRI vs MLYS Comparison

CPRI vs MLYS Comparison

Compare CPRI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

HOLD

Current Price

$26.02

Market Cap

3.2B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$36.99

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPRI
MLYS
Founded
1981
2019
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.1B
IPO Year
2011
2023

Fundamental Metrics

Financial Performance
Metric
CPRI
MLYS
Price
$26.02
$36.99
Analyst Decision
Buy
Strong Buy
Analyst Count
11
6
Target Price
$26.36
$46.40
AVG Volume (30 Days)
2.7M
1.6M
Earning Date
11-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,369,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.86
$8.24
52 Week High
$28.27
$47.65

Technical Indicators

Market Signals
Indicator
CPRI
MLYS
Relative Strength Index (RSI) 61.14 40.09
Support Level $25.64 $35.77
Resistance Level $28.27 $44.13
Average True Range (ATR) 0.95 1.93
MACD 0.00 -0.64
Stochastic Oscillator 53.04 14.95

Price Performance

Historical Comparison
CPRI
MLYS

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: